Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
Molecular imaging and quantification of neurological diseases
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
Butt BP, Sorbye H, Ladekarl M, Stokmo HL, Lothe IMB, Fawad H, Tabaksblat EM, Revheim ME, Dybdahl B, Couvelard A, Perren A, Hjortland GO(2026) Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma J Neuroendocrinol, 38(4), e70168 DOI 10.1111/jne.70168, PubMed 41911950
Astrup GL, Siksjø MK, Aass N, Alves G, Brønnick KK, Hjermstad MJ, Kaasa S, Karlsson AT, Landrø NI, Tysnes OB, Seierstad T, Yri OE(2025) Cognitive function in long-term survivors after treatment for brain metastases compared with normative samples Neurooncol Pract, 13(1), 178-188 DOI 10.1093/nop/npaf083, PubMed 41798131
Brandal SHB, Mo T, Fangberget A, Nilsen LB, Geier OM, Bjørndal H, Holmen MM, Engebråten O, Garred Ø, Hole KH, Seierstad T(2026) MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer Cancers (Basel), 18(3) DOI 10.3390/cancers18030393, PubMed 41681863